Million pound milestone in Emily’s memory

A family which has raised more than a million pounds to fund a research project into the most aggressive type of brain tumour has unveiled a plaque at the University of Edinburgh laboratory where the work takes place. 

The Emily Morris Fund, set up in memory of a woman from London who died from a brain tumour aged just 31, was established in 2017 in collaboration with The Brain Tumour Charity. 

Emily’s father, Jack Morris, then became Chair of Trustees at the organisation.

Now he and his family have seen for themselves how their fundraising is helping to screen thousands of drugs to see if any have the potential to treat glioblastoma. 

The project is co-funded by Cancer Research UK and is believed to be the largest of its kind in the world: an unbiased screening of drugs in human glioblastoma cell models. 

Emily first became unwell with headaches and what doctors thought was a flu virus in 2015 when she was 29. 

Then her heart rate rocketed for no apparent reason and a cardiac specialist prescribed her medication but couldn’t find the underlying cause. 

When she began to experience a strange smell and taste up to 20 times a day, she was referred to an ear, nose and throat specialist who sent Emily for an MRI scan.  

Expecting nothing out of the ordinary, Emily went to find out the results on her own and was shocked when a consultant told her she had a brain tumour and needed urgent surgery. 

That craniotomy removed much of the tumour and confirmed it was a glioblastoma multiforme, one of the most aggressive and difficult to treat brain cancers. 

Emily’s treatment included 30 sessions of radiotherapy and nine rounds of chemotherapy, but the tumour returned. 

Emily’s father Jack said: “Emily had six months after her initial treatment where she did pretty well. Following that it was then a process of, as I used to say, trying hold back a tsunami.” 

In November/December 2016 Emily’s oncologist said she was fighting an uphill battle, and her family agreed that she should come home. 

Jack continued: “I had a moment that I’ll treasure for the rest of my life with Emily before she died. I was just sitting with her and at this time she couldn’t speak and I did a little wave and said ‘I love you’ and she just said to me ‘love you’. I don’t know how she found the words but they were the last words she ever said to me.” 

Emily died on 3 January 2017 and as she had been such a colourful character who loved jewellery, her mum Susan started making bracelets to sell in her memory. 

Friends and family far and wide organised marathons, bike rides and numerous other challenge events to raise money in Emily’s memory. Her family used these proceeds to set up The Emily Morris Fund and sought advice from The Brain Tumour Charity.  

The Charity told them about Professor Neil Carragher’s research at the University of Edinburgh and they were “absolutely blown away” by his efforts to find treatments for glioblastoma and decided to support it.  

Jack said: “Funding research through The Brain Tumour Charity, wherever it needs to be in the world, by the best practitioners, by the best institutions, is the lifeblood of finding a cure for this awful disease.” 

Emily’s brother, Bobby, added: “We will always keep Emily’s memory alive because we talk about her a lot.

“Whenever we’re at a family dinner or a birthday, we’ll always do a little toast to her and just make sure that she’s remembered … Our family will always be a family of five people, we’re not a family of four.” 

You can find out more about Professor Carragher’s research here:

https://www.thebraintumourcharity.org/news/research-news/finding-new-drugs-for-treating-glioblastoma/ 

And read Emily’s full story here: https://www.thebraintumourcharity.org/emily-morris-fund/ 

Experts discuss ways to improve brain tumour diagnosis in Scotland

A Glasgow-based company which is developing a diagnostic tool to detect brain tumours is one of the organisations taking part in roundtable discussions today – 5 February – to review the brain tumour diagnosis pathway in Scotland. 

GPs, NHS representatives, researchers, representatives from the Chief Scientist’s Office, the Scottish Steering Committee and The Brain Tumour Charity – representing the patient voice – are also taking part in the meeting at The Royal College of Physicians in Edinburgh.  

More than 1,000 people in Scotland are diagnosed with a brain or central nervous system tumour each year1 so there is an urgent need to prioritise better care. In addition, The Charity’s Improving Brain Tumour Care surveys show one in three people visit their GP more than five times before they are diagnosed.  

Now Dxcover Limited is working alongside researchers at the University of Edinburgh to develop a blood test and AI algorithms that could enable earlier diagnosis in primary care settings by analysing blood samples to look for signs of a brain tumour. Early research suggests that this technology could offer a promising diagnostic tool, although more testing is required.

Dxcover
Dxcover1

Cameron Miller, Director of Policy and Strategy at The Brain Tumour Charity said: “This roundtable is a stepping stone to ensure that the right conversations are taking place while these diagnostic tools are being developed.

“When they are ready for patients, we want to ensure that they can access them as quickly as possible. It is also key to ensuring policymakers truly understand the barriers to brain tumour diagnosis and the need to improve current diagnostic pathways.” 

Brain tumours can be hard to diagnose due to their non-specific symptoms, including headaches, vomiting and visual disturbances. An early diagnostic test to help identify which people with these symptoms are most likely to have a brain tumour would help prioritise demand on imaging facilities such as MRI and CT scans.  

Dxcover is currently running a performance evaluation study across seven sites in the UK and Europe, to understand the effectiveness and viability of their technology.  

Prof. Matthew J. Baker, CEO of Dxcover said: “Dxcover has patients at the heart of its thinking. This roundtable is key to changing the picture for brain tumour patients and one which we are excited to be a part of.  

“We have recently launched our EMBRACE study – a pan-Europe 2,200 patient performance evaluation of the Dxcover® brain cancer liquid biopsy which will enable CE marking and provide a much-needed tool for patients.” 

Dr Paul Brennan, Reader and Honorary Consultant Neurosurgeon at the University of Edinburgh said: “During several clinical studies involving patients in Scotland we have demonstrated that the Dxcover test is an efficient and effective strategy for brain tumour detection. 

“The next step is to find the best route to implement this test into routine care and this roundtable brings together the stakeholders needed to achieve that.” 

To find out more about The Brain Tumour Charity’s work with policymakers and healthcare professionals, visit thebraintumourcharity.org